Enantone 1-Month DPS 3.75 mg/Enantone 3-Month DPS 11.25 mg/Enantone 6-Month DPS 30 mg Contraindications

Enantone 1-Month DPS 3.75 mg: Endometriosis, Uterine Myoma, Central Precocious Puberty: Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH-RH or LH-RH derivatives.
Pregnant women or women having possibilities of being pregnant, or nursing mothers (see Use in Pregnancy & Lactation).
Patients with abnormal genital bleeding of indeterminable nature: There is a possibility of malignant disease.
Premenopausal Breast Cancer: Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH-RH or LH-RH derivatives.
Pregnant women or women having possibilities of being pregnant, or nursing mothers (see Use in Pregnancy & Lactation).
Prostate Cancer: Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH-RH or LH-RH derivatives.
Enantone 3-Month DPS 11.25 mg: Hypersensitivity to active substance or any of excipients listed in Description or to any other synthetic GnRH analogues or derivatives.
Pregnancy.
Breast-feeding.
Contraindicated in the presence of undiagnosed vaginal bleeding.
Enantone 6-Month DPS 30 mg: Hypersensitivity to leuprorelin or other synthetic GnRH analogues, polylactic acid or to any of the ingredients of the suspension medium listed in Description.
Demonstrated non-hormone-dependent carcinoma.
ENANTONE 6 MONTH DPS is not intended for the use in women and is generally contraindicated during pregnancy and lactation.